Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VTVT 
vTv Therapeutics Inc (VTVT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: VTVT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -68.76% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.87M USD | Price to earnings Ratio - | 1Y Target Price 35 |
Price to earnings Ratio - | 1Y Target Price 35 | ||
Volume (30-day avg) 35262 | Beta 0.63 | 52 Weeks Range 12.12 - 29.19 | Updated Date 03/30/2025 |
52 Weeks Range 12.12 - 29.19 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.37 |
Earnings Date
Report Date 2025-03-11 | When Before Market | Estimate - | Actual -0.552 |
Profitability
Profit Margin - | Operating Margin (TTM) -2285.7% |
Management Effectiveness
Return on Assets (TTM) -41.48% | Return on Equity (TTM) -362.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8615046 | Price to Sales(TTM) 44.62 |
Enterprise Value 8615046 | Price to Sales(TTM) 44.62 | ||
Enterprise Value to Revenue 8.47 | Enterprise Value to EBITDA -2.11 | Shares Outstanding 2612260 | Shares Floating 883711 |
Shares Outstanding 2612260 | Shares Floating 883711 | ||
Percent Insiders 38.82 | Percent Institutions 14.95 |
Analyst Ratings
Rating 5 | Target Price 35 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
vTv Therapeutics Inc
Company Overview
History and Background
vTv Therapeutics Inc., founded in 2015 (spun out from High Point Pharmaceuticals), focused on developing orally delivered treatments for metabolic diseases. Their focus shifted, but initially targeted type 1 diabetes treatment.
Core Business Areas
- Pharmaceutical Development: vTv Therapeutics focused on developing novel small molecule drug candidates. The company's pipeline aimed to address diseases with significant unmet medical needs, including those related to inflammation, and other disease states. However, they have struggled to get drugs approved. As of November 2023, they announced a strategic shift following clinical trial results.
Leadership and Structure
The leadership structure consists of a Board of Directors and an executive management team. The precise structure has evolved following strategic shifts and financial difficulties.
Top Products and Market Share
Key Offerings
- TTP399: An investigational oral small molecule designed to be a selective glucokinase activator for treating type 1 diabetes. It failed in Phase 3 trials and vTv has moved away from diabetes focus. There is no current market share data as it's not approved. Competitors previously were companies such as Sanofi (SNY) and Novo Nordisk (NVO) developing diabetes treatments.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and rapidly evolving. It involves the discovery, development, manufacturing, and marketing of medications. Regulatory hurdles and clinical trial success are critical factors.
Positioning
vTv Therapeutics has historically occupied a niche within the metabolic disease space, but its unsuccessful trials have impacted its positioning and competitive advantages.
Total Addressable Market (TAM)
The diabetes market is estimated to be in the tens of billions of dollars annually. vTv's previous positioning targeted a portion of this TAM but it is difficult to quantify due to trial failures.
Upturn SWOT Analysis
Strengths
Weaknesses
- Limited Financial Resources
- Clinical Trial Failures
- Uncertain Strategic Direction
Opportunities
- Potential Partnerships
- Repurposing Existing Assets
Threats
- Regulatory Hurdles
- Competition from Larger Pharmaceutical Companies
- Funding Constraints
Competitors and Market Share
Key Competitors
- LLY
- NVO
- SNY
Competitive Landscape
vTv Therapeutics faces significant disadvantages compared to larger, more established pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to drug development setbacks.
Future Projections: Future projections are highly uncertain and dependent on new strategic directions.
Recent Initiatives: Recent initiatives include a strategic shift following clinical trial results, implying they are looking for new products or direction.
Summary
vTv Therapeutics is a struggling pharmaceutical company with a history of clinical trial failures and limited financial resources. Its future is highly uncertain and dependent on finding a new, successful strategic direction. The company faces intense competition and significant funding challenges. Current financials and market share are weak reflecting the company's struggles.
Similar Companies
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
NVO
Novo Nordisk A/S
NVO
Novo Nordisk A/S
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About vTv Therapeutics Inc
Exchange NASDAQ | Headquaters High Point, NC, United States | ||
IPO Launch date 2015-07-30 | CEO, President & Chairman of the Board Mr. Paul J. Sekhri M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://vtvtherapeutics.com |
Full time employees 23 | Website https://vtvtherapeutics.com | ||
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.